Loading news...
David Charles Lubner, a director at Arcellx, exercised 6,000 shares, which were sold immediately on Jan. 20, 2026, resulting in a transaction value of approximately $450,000. This disposition represented 21.69% of Lubner's direct holdings, and holds over 21,000 shares post-transaction.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, is advancing both its scientific foundation for its D-Domain platform technology and commercial preparedness for anito-cel for the potential treatment of multiple myeloma with three presentations at the 2026 Tandem Meetings. One presentation reinforces anito-cel's unique.
Here is how Arcellx, Inc. (ACLX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Arcellx, Inc. (NASDAQ: ACLX - Get Free Report) insider Christopher Heery sold 5,882 shares of the business's stock in a transaction on Wednesday, January 14th. The stock was sold at an average price of $68.51, for a total value of $402,975.82. Following the transaction, the insider directly owned 23,749 shares in the company, valued at $1,627,043.99.
Pre-Market Stock Futures: Futures are trading higher as we get ready to start a holiday-shortened trading week after an outstanding triple-witching Friday rally that may have kicked the "Santa Claus" rally into high gear. All of the major indices, including the Russell 2000, finished the day higher, and Oracle Corp. (NYSE: ORCL), which has been... Here Are Monday's Top Wall Street Analyst Research Calls: BlackSky Technology, Cummins, Lamb Watson, Ollie's Bargain Outlet, Sealed Air, Volaris, and More.
Arcellx (ACLX) is positioned to disrupt multiple myeloma cell therapy with anito-cel, leveraging superior efficacy, safety, and scalable manufacturing. ACLX's $576 million cash runway extends into 2028, mitigating dilution risk and supporting its transition to commercialization post-2026 launch. Anito-cel's 96% ORR, 74% CR/sCR, and clean safety profile differentiate it from competitors, especially against Carvykti's neurotoxicity concerns.
Arcellx Inc. (NASDAQ: ACLX) shared new data on Saturday from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma (RRMM).
Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data are being presented during an oral presentation at the 67th American Society o.
Arcellx, Inc. (NASDAQ: ACLX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have given a buy recommendation and one has assigned
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will host an Investor Relations event on Saturday, December 6, 2025 at 8:00 p.m. ET. The event will include a panel of clinician experts and a discussion of the latest data from the Company's Phase 2 pivotal iMMagine-1 study in patients wit.
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.48 per share a year ago.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Cash, cash equivalents, and marketable securities: As of September 30, 2025, Arcellx had cash, cash equivalents, and marketable securities of $576.0 mi.
Arcellx, Inc. (NASDAQ: ACLX - Get Free Report) has received a consensus rating of "Moderate Buy" from the fourteen research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has assigned a
Arcellx (ACLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcellx, Inc. (NASDAQ:ACLX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Rami Elghandour - Chairman of the Board, CEO & President Christopher Heery - Chief Medical Officer Michelle Gilson - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Good afternoon, everyone. Welcome to the session of the Morgan Salary Global Healthcare Conference.
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divestiture of non-core assets, new leadership, and a focus on high-growth hospital monitoring technologies. Eli Lilly remains a core holding due to its leadership in diabetes and obesity treatments, robust pipeline, and potential to triple revenues by 2030.
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $0.51 per share a year ago.
Arcellx (ACLX) Q2 Revenue Drops 72%